ADSCC develops virus-free, clinical-grade induced pluripotent stem cells

In a breakthrough that could reshape the landscape of regenerative medicine, the Abu Dhabi Stem Cells Center (ADSCC) has developed clinical-grade induced pluripotent stem cells (iPSCs) without relying on viruses. This is the first time such a feat has been accomplished in the Middle East, and it also places Abu Dhabi on the global map for cutting-edge medical research.

By adhering to rigorous Good Manufacturing Practice (GMP) protocols, ADSCC ensures that these iPSCs meet international clinical standards, heralding a new era in precision medicine.

How does it work?

The magic behind iPSCs lies in their ability to transform ordinary cells into something extraordinary. Scientists at ADSCC reprogram adult cells — think skin or blood cells — back to a near-embryonic state. Once reprogrammed, these iPSCs can morph into any type of cell in the human body. What's unique about ADSCC's approach is their virus-free protocol. While conventional methods often use viruses to induce this transformation, ADSCC sidesteps the risks of genetic alteration, reducing the chances of complications like tumor formation.

"Our proprietary, virus-free method is a game-changer," said Professor Yendry Ventura, CEO of ADSCC. "It's safer, more reliable, and adheres to the highest clinical standards."

The process results in patient-specific cells, which means doctors can create tailored treatments without worrying about immune rejection or the need for immunosuppressants.

Why does it matter?

This isn't just a scientific milestone; it's a lifeline for patients battling chronic and debilitating conditions. From neurodegenerative diseases like Parkinson's and Alzheimer's to diabetes, iPSCs hold the potential to revolutionize treatment options. Imagine a patient with diabetes receiving custom pancreatic cells derived from their own body — a treatment that could eliminate the disease's root cause.

"This accomplishment is about more than innovation," said Ventura. "It's about hope. Hope for individuals who, until now, had limited options."

The ability to produce these cells locally in Abu Dhabi ensures top-notch quality control and means faster access to life-changing therapies.

The context

The development comes at a time when the UAE is making strides toward becoming a global leader in healthcare innovation. With state-of-the-art GMP facilities and a highly skilled team, ADSCC is well-positioned to lead the charge in stem cell research. The center's collaboration with Kyoto University and Japan-based biotech company Rege Nephro underscores its commitment to international partnerships. Together, they aim to develop therapies for diabetes using pancreatic beta cells derived from iPSCs.

"By creating iPSCs from a patient's own cells, we can generate therapeutic cells tailored to their needs," said Professor Angelo Vescovi, an advisor at ADSCC. "For neurodegenerative conditions, these cells could be injected back into the brain or spinal cord, offering a real chance at recovery."

ADSCC's achievement highlights its dedication to scientific excellence and aligns perfectly with the UAE's vision of fostering innovation in healthcare. With a robust foundation for future research and biomanufacturing, the center is poised to usher in a new chapter in personalized medicine.